Cancer Chemotherapy & Pharmacology Flashcards

1
Q

Cancer

A

= uncontrolled growth and spread within the body of abnormal forms the body’s own cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cancer cells

A
  1. uncontrolled proliferation
  2. de-differentiation
    - immature
    - loss of function
    - ‘immortal’
  3. Invasiveness
    - actively leave tissue of origin
  4. Metastasis
    - can proliferate in foreign tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chemotherapy

A

Chemotherapy = drugs that are selectively toxic to the invading organism (or cancer) but harmless or having minimal effects on the host (or normal cells)

Goal of chemotherapy is aimed at near total cancer cell kill Used in conjunction with surgery and radiotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anti-cancer drug classes: cytotoxic agents (DNA)

A

Alkylating
Antimetabolites
Cytotoxic antibodies
Plant derivatives and similar compounds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Anti-cancer drug classes: hormonal

A

Hormones/antagonists

  • disrupt hormone dependent tumour growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Anti-cancer drug classes: non-cytotoxic

A

Protein kinase inhibitors

Monoclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cytotoxic drugs: Alkylating agents

A

Eg. Cyclophosphamide, cisplatin, dacarbazine, ifosfamide, melphalan

Form intra-strand covalent bonds in DNA

  • impedes transcription & replication
  • induces apotosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclophosphamide uses

A

Use:
• Strong effects on lymphocytes
• Anti-cancer drug and immunosuppressant
lymphoma, breast cancer, leukemia, myeloma
• One of most commonly used alkylating agents • Given orally or i.v.
• Inactive until metabolized by P450 in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cyclophosphamide side effects

A

immune suppression, carcinogenic,

bone marrow toxicity (myelosuppression), GIT lining damage, nausea/vomiting, haemorrhagic cystitis (bladder), alopecia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cytotoxic drugs: Antimetabolites

A

Eg. Methotrexate, 5-fluorouracil, mercaptopurine, cytarabine

Block metabolic pathways involved in DNA / RNA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Methotrexate

A

• Folate is essential for synthesis of purine nucleotides (building blocks of DNA/RNA)
• Inhibits dihydrofolate reductase
=> inhibits production of purines/pyrimidines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Methotrexate uses and side effects

A

Use:
• Orally (also i.m., i.v., i.t.) • Anticancer:-
Breast and lung cancer, leukemia, lymphoma • Immunosuppressant (Rheumatoid Arthritis)

Side effects: Bone marrow toxicity (myelosuppression), GIT lining damage, nausea/vomiting, pulmonary and liver toxicity, hair loss (alopecia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cytotoxic drugs: Cytotoxic antibiotics

A

Eg. Doxorubicin, mitomycin, dactinomycin, epirubicin

From microbes (Streptomyces spp.), too toxic as antibiotic drugs Prevent cell division via multiple effects on DNA/RNA synthesis - Bind to DNA and/or - inhibit topoisomerase enzyme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Doxorubicin mechanism

A
  • Topoisomerase II inhibitor (DNA gyrase)
  • Binds to DNA (between base pairs)
  • Traps DNA bound topoisomerase II
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Doxorubicin use

A
  • Given i.v. (possible necrosis at injection site)
  • Broad use for solid and blood tumours
  • Not given with radiotherapy (cumulative toxicity)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Doxorubicin side effects

A

myelosuppression, nausea/vomiting, hair loss (alopecia), cardiotoxicity (high doses)

17
Q

Non cytotoxic drugs 1: Antibodies

Antibody mechanisms

A

neutralise and flag invaders for destruction

Inhibit growth factors or GF receptors

  1. Bind to agonist or receptor (inhibition)
  2. Increase receptor internalisation
  3. complement-dependent cytotoxicity 2. anti-body-dependent cell-mediated cytotoxicity (ADCC) via TC (CTL) cells
18
Q

Antibodies: Herceptin

A

HER2 is an oncogenic growth factor receptor (human epidermal growth factor receptor 2)
• Expressed breast cancer cells in ~25% breast cancer patients (aggressive form)
• Often used in combination with a taxane (e.g. docetaxel)

19
Q

Herceptin mechanisms

A
Mechanism
A. Prevents receptor activation
B. Induces anti-body-
dependent, cell mediated
cytotoxicity (ADCC)
C. Enhances receptor
internalization
=> decreases receptor active number
20
Q

Herceptin side effects

A

Side effects:
Hypotension, chills / fever, GI disturbances, fatigue, may induce hypersensitivity reactions
Possible liver and cardio toxicity

21
Q

Non-Cytotoxic drugs 2: Tyrosine kinase inhibitors

A

e.g imatinib

Inhibit protein kinases involved in growth factor receptor signaling => Targeted therapeutics (= lower side effects than cytotoxics)

22
Q

Imatinib - uses and SE

A
  • inhibits oncogenic cytoplasmic kinase (Bcr/Abl)
  • Unique oncogene in chronic myeloid leukemia (CML)
  • Also inhibits kinase of platelet derived growth factor

Use:
• Given orally for CML • Some GIT tumors

Side effects:
GIT disturbances (pain, diarrhoea), nausea, headaches, fatigue, ~rashes
23
Q

Hormonal anti-cancer drugs: (non-cytotoxic 3)

A

E.g Tamoxifen (anti oestrogen);

Used in hormone-dependent tumors (breast, uterus, prostate) Þ Hormone receptors expressed in malignant cells

1: Suppress hormone synthesis/secretion
2: Antagonise hormone action

24
Q

Tamoxifen mechanism

A

Mechanism:
• Competes with endogenous oestrogen in breast cells (not in bone or endometrium)
• Inhibits transcription of oestrogen-dependent genes • Decreases expression of some growth factors

25
Q

Tamoxifen use and SE

A

Use:
• Effective in some hormone-dependent breast cancers
• May be preventative (used in high risk women)

Beneficial side effects:
• lowers LDL cholesterol => Risk of heart disease
• Strengthens bones
• Reduces breast cancer risk

Side effects: similar to menopause
Increase uterine cancer risk, and blood clot risk

26
Q

Tamoxifen problems

A

Resistance

already be resistant or develop resistance to effects of anti-cancer drugs

  • Kinetic changes: uptake / metabolism
    (e. g. cyclophosphamide)
  • Dynamic changes: enzyme
    (e. g. methotrexate)
  • Induction of multiple drug resistance (MDR1) gene (P-glycoprotein / abc transp.)
    (e. g. Doxorubicin)

Limited efficacy
Single drugs can have varied effectiveness in many cancers

27
Q

Combination therapy

A
  1. produces synergistic cell kill => increase efficacy (r.r.)
  2. decreases development of resistance
  3. decreases side effects

Guide for combinations
• Have some efficacy when used alone
• Drugs with different limiting side effects
• Use drugs with different mechanisms of action

28
Q

anti Cancer drugs side effects

A

Nausea and vomiting:
Major side effect from many anti-cancer drugs Common reason for decreased patient compliance
Myelosuppression: bone marrow toxicity
Major limiting side effect of many anti-cancer drugs
Results in low blood cell counts (anemia/fatigue, fever, bruising, susc inf.) - neutropenia

29
Q

Side effect management

A

Side effect management
Combination therapy:
Can increase cytotoxic effects on cancers without increasing s.e.

Dosing regimes: larger doses with 2-3 week gaps =>

1: allows bone marrow to recover
2: can get more effective cell kill than more frequent small doses

Pharmacological management:
Nausea and vomiting can be controlled using 5-HT3 receptor antagonists (ondansetron or granisetron) or metoclopramide Folinic acid: used with high doses of methotrexate
G-CSFs

30
Q

SUMMARY

A

• Cytotoxics = more side effects, and more severe
• Targeted therapies = less side effects, very expensive
• Problems include lack of efficacy, resistance and side effects
• Nausea and vomiting = big problems for seeing cycles completed.
• Combination therapy, different dosing regimes and pharmacological management
helps get around several of the problems.